AnaptysBio, Inc. Common Stock
ANAB Real Time Price USDRecent trades of ANAB by members of U.S. Congress
No Congress Trading data for this ticker
Congress Trading Dashboard
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
---|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
---|
Recently reported changes by institutional investors
Quarterly net insider trading by ANAB's directors and management
Government lobbying spending instances
No Corporate Lobbying instances for this ticker
Corporate Lobbying DashboardEstimated quarterly lobbying spending
No Corporate Lobbying data for this ticker
Corporate Lobbying DashboardNew patents grants
-
Patent Title: Method of treating autoimmune disease with antibodies against il-33 Jun. 04, 2024
-
Patent Title: Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) Jun. 07, 2022
-
Patent Title: Antibodies directed against programmed death-1 (pd-1) Oct. 26, 2021
-
Patent Title: Method of treating pustular psoriasis with antibodies directed against interleukin 36 receptor (il-36r) Sep. 28, 2021
-
Patent Title: Antibodies directed against lymphocyte activation gene 3 (lag-3) Nov. 17, 2020
-
Patent Title: Method of treating inflammatory disorder with antibodies directed against interleukin-33 (il-33) Nov. 17, 2020
-
Patent Title: Antibodies directed against programmed death-1 (pd-1) Aug. 11, 2020
-
Patent Title: Antibodies directed against interleukin 36 receptor (il-36r) Jan. 07, 2020
-
Patent Title: Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) Dec. 17, 2019
-
Patent Title: Antibodies directed against interleukin-33 (il-33) and methods of making and using Aug. 28, 2018
-
Patent Title: Antibodies directed against nerve growth factor (ngf) Apr. 24, 2018
-
Patent Title: Antibodies directed against programmed death-1 (pd-1) Nov. 14, 2017
-
Patent Title: Methods of generating libraries and uses thereof May. 02, 2017
-
Patent Title: Antibodies directed against il-17 May. 03, 2016
-
Patent Title: Methods of generating libraries and uses thereof Feb. 16, 2016
-
Patent Title: Humanized antibodies directed against complement protein c5 Sep. 15, 2015
-
Patent Title: Antibodies directed against nerve growth factor (ngf) Jan. 06, 2015
-
Patent Title: Methods of generating libraries and uses thereof Apr. 01, 2014
-
Patent Title: Methods of generating libraries and uses thereof Dec. 10, 2013
Federal grants, loans, and purchases
No Government Contracts for this ticker
Government Contracts DashboardEstimated quarterly amount awarded from public contracts
Number of mentions of ANAB in WallStreetBets Daily Discussion
Recent insights relating to ANAB
Recent picks made for ANAB stock on CNBC
ETFs with the largest estimated holdings in ANAB
Shareholder
|
Shares Held
|
---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view ANAB Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.